2.35
-0.20 (-7.84%)
| Penutupan Terdahulu | 2.55 |
| Buka | 2.60 |
| Jumlah Dagangan | 417,043 |
| Purata Dagangan (3B) | 625,731 |
| Modal Pasaran | 22,457,164 |
| Harga / Jualan (P/S) | 2.72 |
| Harga / Buku (P/B) | 7.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 25 Jul 2023 - 31 Jul 2023 |
| Margin Keuntungan | -14.74% |
| Margin Operasi (TTM) | 7.86% |
| EPS Cair (TTM) | 1.05 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 54.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 186.77% |
| Nisbah Semasa (MRQ) | 2.79 |
| Pulangan Atas Aset (ROA TTM) | 0.98% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.57% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Alimera Sciences, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 0.0 |
| Purata | 0.17 |
|
Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 5.34% |
| % Dimiliki oleh Institusi | 86.54% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |